Good afternoon everyone and welcome to the Stocktwits Top 25 Newsletter for Week 38, 2020.
The Stocktwits Top 25 reports the top 25 performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here’s your Stocktwits Top 25 Lists for Week 38:
ST Top 25 S&P 500
15 of the 25 stocks in the ST Top 25 S&P 500 were in the red but the top 5 all finished green. Winners win.
L Brands leapt from #14 to #5 following its +7.7% week.
Amazon, Old Dominion, and Chipotle all fell at least 5%. Hold the guac.
2 freshmen joined the list. Welcome, Lennar and T-Mobile.
The Stocktwits Top 25 S&P 500 Momentum Meter fell 0.61% while the S&P 500 dropped 0.64%. The differential of 0.03% indicates that the top stocks in the S&P 500 were in line with the index.
The Big Cap Nasdaq 100
The ST Top 25 Nasdaq 100 list bucked its Week #37 bloodbath.
12 of the 25 stocks on the ST Top 25 N100 list closed green.
The 2 leaders, Zoom and Tesla each notched double-digit gains. Relentless.
Seattle Genetics was this week’s Top Dawg. $SGEN was up 20.7%.
eBay dropped 7.8%. More on this Sinner below.
The ST Top 25 Nasdaq 100 Momentum Meter rose 1.48% for Week #38 while the full Nasdaq 100 lost 1.36%. The 2.84% differential suggests the top stocks outperformed the full index.
Small-Cap Russell 2000
24 of the 25 stocks on the ST Top 25 R2K list closed green. Strength in numbers.
Inovio Pharma hopped back on the list after a brief hiatus. The biotech company soared 68%, see more below.
Waitr Holdings botched what would be a perfect week. It was the only stock in the red.
4 new Freshmen made the list: Brainstorm Cell Therapeutics, CymaBay Therapeutics, Veritone, and Inovio Pharma.
The ST Top 25 R2K Momentum Meter jumped 18.66% while the Russell 2000 index gained 2.64%. The 16.02% differential suggests that the top stocks smoked the index. Winners win 🤷♂️
ST Top 25 TOP DAWG OF THE WEEK 🐶
The ST Top 25 Top Dawg for Week 37, 2020 is Seattle Genetics.
$SGEN spiked 20.65% this week after Merck & Co ($MRK) announced plans to pay up to $4.5 billion for two of its cancer drugs.
Seattle Genetics and Merck plan to develop an experimental drug, ladiratuzumab vedotin (LV). LV is in phase 2 clinical trials for breast cancer and other solid tumors.
Seattle Genetics CEO Clay Siegall had this to say:
Collaborating with Merck on ladiratuzumab vedotin will allow us to accelerate and broaden its development program in breast cancer and other solid tumors, including in combination with Merck’s KEYTRUDA, while also positioning us to leverage our U.S. and European commercial operations. The strategic collaboration for TUKYSA will help us reach more patients globally and benefit from the established commercial strength of one of the world’s premier pharmaceutical companies.
Incredible. Best of luck. 👏
Here’s the YTD chart:
The Winners 📈
△ #2 N100 – Tesla, Inc rebounded and Elon got $13 billion richer. 😉 lol
$TSLA charged up 19% after a kiss off the 50 day moving average. It maintained its #2 spot on the ST Top 25 N100 List.
Tesla hosts its “Battery Day” next Tuesday. Musk tweeted:
Here’s the YTD chart.
△ #8 S&P 500 – Fedex Corp reached prices not seen since 2018. The transportation stock gained 4.29% and moved from #15 to #8 on the ST Top 25 S&P 500 list.
$FDX reported better than expected earnings on Tuesday.
Here are the numbers:
EPS: $4.87 vs $2.69 est.
Revenue: $19.3B vs $17.55B est.
And here’s a statement from CFO Alan B. Graf, Jr.:
While business demand improved in the first quarter, continued uncertainties cloud our ability to forecast full-year earnings. However, we expect to continue to benefit from our strong position in the U.S. and international package and freight markets, yield improvement opportunities and cost management initiatives.
$FDX is up 63% YTD.
△ #12 R2K – Inovio Pharmaceuticals ripped 69% this week on comments from the CEO. $INO jumped back onto the ST Top 25 R2K this week as a Freshman in the #12 spot.
CEO J. Joseph Kim spoke at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday and had encouraging words. Kim said a paper detailed with phase 1 results of $INO’s coronavirus vaccine candidate INO-4800 is currently in peer review with expected results in the next few weeks. Kim also expects phase ⅔ testing for the vaccine to begin soon and he is “very confident that we will be able to do this with external funding,”.
Here’s the YTD chart:
△ #13 R2K – Digital Turbine Inc. Shares of the mobile software company exploded 35.5% higher this week and closed at new all time highs. Digital Turbine moved up 9 spots from #22 to #13 on the ST Top 25 R2K List. 💪
$APPS jumped 13% on Tuesday and was up another 12.5% on Wednesday.
Here’s the YTD chart:
The Sinners 📉
▼ #23 N100 – eBay Inc fell 8% in Week 38 and lost 8 spots on the ST Top 25 N100 List dropping from #15 to #23.
In Week 37, eBay founder Pierre Omidyar stepped back from board responsibilities and transitioned into the role of Director Emeritus. Pierre had this to say, “For 25 years, I’ve watched with pride as the company I created enabled economic opportunity for people around the world. With sound strategy and leadership in place, I can transition to the role of Director Emeritus with confidence,”.
Elliott Management gave up their board seat as well. Former CFO of CIT Group, Carol Hayles and LinkedIn executive Mohak Shroff will fill the vacant seats.
▼ Lululemon Athletica Inc is a back-to-back Sinner. The company reported better than expected Q2 earnings in Week 37 but the stock fell 13%. Selling continued this week as $LULU dropped another 6%, falling off the ST Top 25 N100 List entirely.
$LULU is trading at levels not seen since June. Will this act as support? Time will tell.
See Y’all Next Week
